ArticleFrontiers in cell and developmental biology2026
Machine learning-based early prediction of severe pneumonia risk in hospitalized leukemia patients: a dual-center retrospective cohort study.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe pneumonia is a major infectious complication in patients with leukemia and may rapidly progress to respiratory failure or septic shock. Disease- and treatment-related immunosuppression increases susceptibility, yet population-specific early risk-stratification tools are limited. Objectives: To develop and externally validate a machine learning model for predicting severe pneumonia in hospitalized patients with leukemia. Methods: Data from 2,978 leukemia patients at two Chinese hospitals were retrospectively analyzed. The derivation cohort was divided into training and internal test sets; SMOTE was applied only to the training set. LASSO and SVM-RFE were used for predictive feature selection, eight machine learning algorithms were compared, and RCS was used for exploratory association analysis. The final model was presented as a nomogram. Results: Seven predictors were retained: age, history of myelosuppression, acute lymphoblastic leukemia (ALL) subtype, cardiac insufficiency, atrial fibrillation, red blood cell distribution width-standard deviation (RDW-SD), and prothrombin time activity. Logistic regression showed the best generalizability, with an area under the curve (AUC) of 0.801 in external validation. Sensitivity analyses showed similar discrimination with multiple imputation and complete-case analysis. Conclusion: We developed and externally validated an interpretable model for severe pneumonia in hospitalized patients with leukemia. Because direct programmed-cell-death biomarkers were not measured and SMOTE substantially altered training prevalence, mechanistic interpretation and absolute-risk calibration require caution. Prospective recalibration and clinical-impact evaluation are needed before routine use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.